Atherosclerotic Cardiovascular Disease

A potential target for improving residual lipid-related risk for atherosclerotic CVD is reduction in triglyceride levels. Studies have shown eicosapentaenoic acid is effective in lowering triglyceride levels and reducing the risk for ischemic events in patients with elevated triglyceride levels already taking statin therapy.

Safety, efficacy and tolerability of inclisiran (The Medicines Company) in patients with atherosclerotic CVD and elevated LDL despite optimal medical therapy.

PHILADELPHIA — People at high risk for CVD, as assessed by risk factors, 10-year atherosclerotic CVD risk score and biomarkers, also have elevated risk for cancer, according to research presented at the American Heart Association Scientific Sessions.

ATLANTA — Although progress has been made in diagnosing and treating patients with familial hypercholesterolemia, more work is needed in these areas, according to a presentation at the FH Foundation’s FH Global Summit.

Patients with familial hypercholesterolemia who were treated in U.S. specialty clinics had a harder time achieving LDL less than 100 mg/dL than those who had atherosclerotic CVD at the start of lipid-lowering therapy.

Statins have pleiotropic effects, ie the ability to reduce heart disease risk and CV death via an unknown mechanism, certainly beyond the LDL cholesterol lowering that they can achieve.

It is well known that HMG-CoA reductase inhibitors reduce LDL, a surrogate marker in atherosclerotic disease, as well as primary and secondary CHD events, the need for revascularization and ischemic stroke.